Overview

• CEO Stephen Gillett announced the wind-down and layoffs in an internal memo, and a company spokesperson confirmed the end of device manufacturing and support.
• Verily will continue supporting active clinical studies that use its Numetric Watch to fulfill existing commitments.
• Leadership says resources are being reallocated to precision health, artificial intelligence, and data-driven tools.
• The company did not disclose how many employees were affected, and departing staff were promised severance and transition assistance.
• The shift aligns with Alphabet’s broader cost reductions and AI investment strategy following earlier moves such as the sale of Verily’s insurance business to Elevance Health.